| Literature DB >> 29966383 |
Jan Schjøtt1,2, Ylva Böttiger3, Per Damkier4,5, Linda Amundstuen Reppe6, Jens Peter Kampmann7, Hanne Rolighed Christensen8, Olav Spigset9,10.
Abstract
Background: The aim of this study was to compare use of references in responses from Scandinavian drug information centres (DICs).Entities:
Keywords: adverse effects; breast feeding; complementary medicine; drug information centres; drug information sources; pharmacokinetics; pregnancy; references
Year: 2018 PMID: 29966383 PMCID: PMC6165374 DOI: 10.3390/medicines5030066
Source DB: PubMed Journal: Medicines (Basel) ISSN: 2305-6320
Type of query with total, mean, and range of number of references among the seven Scandinavian drug information centres (DICs) participating in the study.
| Category | Query | Requested Response Time | References | ||
|---|---|---|---|---|---|
| Total | Mean | Range | |||
| Adverse effects | A female patient presents with deep, infected pockets close to the jaw bone, and needs to have these rinsed every fourth to fifth week for the next six months. The patient uses alendronate 70 mg once weekly. Should alendronate be discontinued during treatment? | Within a week | 35 | 5.0 | 3–6 |
| Pharmacokinetics | A male patient with formerly performed gastric bypass needs treatment for | Within 2 days | 41 | 5.9 | 3–14 |
| Pregnancy | A pregnant women manifests with moderate depression (MADRS1 score 29), and there is indication for treatment with an antidepressant. What antidepressant is the first choice of drug during pregnancy? | Within the next day | 21 | 3.0 | 1–9 |
| Complementary medicine | A GP has registered an increasing use of Ginkgo biloba in nursing care homes and home nursing services. He (she) has also registered that ginkgo might increase bleeding time. What documentation exists on this topic, and what is the relevance for concomitant use of, for example, warfarin, acetylsalicylic acid, clopidogrel, and enoxaparin? | None | 40 | 5.7 | 1–17 |
| Polypharmacy | A male patient, 75 years old, has gradually developed impaired cognition for the last five to six months (MMS2 score 18 at examination). He has essential hypertension treated with atenolol 100 mg once daily and losartan/hydrochlorothiazide 100/12.5 mg once daily. His blood pressure was 130/90 mmHg at the latest appointment. He also uses simvastatin 40 mg and acetylsalisylic acid 160 mg once daily. He uses paroxetine 40 mg in the morning for anxiety/depression, diazepam 5 mg as needed, and promethazine/propiomazine3 50 mg at night for sleep. He also uses tolterodine 2.8/4 mg4 once daily for overactive bladder (dosage increased from 1.4/2 mg4 three months ago). The patient does not smoke. Can any of these drugs, or drug interactions, increase the risk of impaired cognition? | None | 74 | 10.6 | 5–17 |
| Breast feeding | A female patient, 13 weeks post partum, presents with active ulcerative colitis. She has earlier been treated with sulfasalazine 500 mg × 3 (discontinued during pregnancy). Can she use sulfasalazine while breast feeding? | None | 33 | 4.7 | 1–11 |
|
|
|
|
| ||
The six drug-related queries from general practitioners (GPs) were simultaneously submitted to the seven DICs during a study period of eight weeks. All GPs asked each query on the same day. Queries were originally asked in Norwegian, Danish, and Swedish languages. Elements in this table have previously been published in another article from our group (17). 1MADRS, Montgomery and Asberg Depression Rating Scale. 2MMS, Mini Mental Status. 3Promethazine is marketed in Norway and Denmark, but not in Sweden. For the Swedish query, we used the drug propiomazine. Both drugs are derivates of phentiazines with antihistaminic and anticholinergic effects. 4Tolterodine is marketed as 2 and 4 mg depot capsules in Norway and Sweden, and as 1.4 and 2.8 mg depot capsules in Denmark.
Type of reference related to type of query for the seven Scandinavian drug information centres (DICs) participating in the study.
| Type of reference | Total n (%) | Type of query and number of references | |||||
|---|---|---|---|---|---|---|---|
| Adverse effects | Pharmacokinetics | Pregnancy | Complementary medicine | Polypharmacy | Breast feeding | ||
| Primary (original studies) | 43 (17.6) | 4 | 8 | 6 | 13 | 2 | 10 |
| Secondary (reviews) | 52 (21.3) | 15 | 14 | 5 | 9 | 4 | 5 |
| Tertiary (drug monographs, handbooks, etc.) | 124 (50.8) | 10 | 13 | 8 | 16 | 61 | 16 |
| DIC database | 22 (9.0) | 5 | 6 | 2 | 1 | 6 | 2 |
| Personal communication | 3 (1.2) | 1 | 0 | 0 | 1 | 1 | 0 |
|
|
|
|
|
|
|
|
|
Figure 1Number and type of references used by the seven Scandinavian drug information centres (DICs) participating in the study.
Figure 2Type of references related to type of query for the seven Scandinavian drug information centres (DICs) participating in the study. Note that the ordinates are displayed with different scales.